S&P 500   3,761.83 (-0.57%)
DOW   30,083.63 (-0.63%)
QQQ   281.92 (-0.02%)
AAPL   146.30 (-0.07%)
MSFT   249.49 (+0.12%)
META   140.81 (+1.32%)
GOOGL   102.37 (+0.93%)
AMZN   120.68 (-0.22%)
TSLA   238.72 (-0.87%)
NVDA   133.40 (+0.99%)
NIO   15.09 (-5.92%)
BABA   84.73 (+0.40%)
AMD   69.03 (+1.60%)
T   15.50 (-2.70%)
MU   54.32 (-0.75%)
CGC   2.98 (-2.93%)
F   12.39 (-0.96%)
GE   66.64 (-1.19%)
DIS   101.14 (+0.34%)
AMC   7.35 (+0.27%)
PYPL   95.08 (+1.33%)
PFE   43.35 (-1.75%)
NFLX   238.26 (+0.65%)
S&P 500   3,761.83 (-0.57%)
DOW   30,083.63 (-0.63%)
QQQ   281.92 (-0.02%)
AAPL   146.30 (-0.07%)
MSFT   249.49 (+0.12%)
META   140.81 (+1.32%)
GOOGL   102.37 (+0.93%)
AMZN   120.68 (-0.22%)
TSLA   238.72 (-0.87%)
NVDA   133.40 (+0.99%)
NIO   15.09 (-5.92%)
BABA   84.73 (+0.40%)
AMD   69.03 (+1.60%)
T   15.50 (-2.70%)
MU   54.32 (-0.75%)
CGC   2.98 (-2.93%)
F   12.39 (-0.96%)
GE   66.64 (-1.19%)
DIS   101.14 (+0.34%)
AMC   7.35 (+0.27%)
PYPL   95.08 (+1.33%)
PFE   43.35 (-1.75%)
NFLX   238.26 (+0.65%)
S&P 500   3,761.83 (-0.57%)
DOW   30,083.63 (-0.63%)
QQQ   281.92 (-0.02%)
AAPL   146.30 (-0.07%)
MSFT   249.49 (+0.12%)
META   140.81 (+1.32%)
GOOGL   102.37 (+0.93%)
AMZN   120.68 (-0.22%)
TSLA   238.72 (-0.87%)
NVDA   133.40 (+0.99%)
NIO   15.09 (-5.92%)
BABA   84.73 (+0.40%)
AMD   69.03 (+1.60%)
T   15.50 (-2.70%)
MU   54.32 (-0.75%)
CGC   2.98 (-2.93%)
F   12.39 (-0.96%)
GE   66.64 (-1.19%)
DIS   101.14 (+0.34%)
AMC   7.35 (+0.27%)
PYPL   95.08 (+1.33%)
PFE   43.35 (-1.75%)
NFLX   238.26 (+0.65%)
S&P 500   3,761.83 (-0.57%)
DOW   30,083.63 (-0.63%)
QQQ   281.92 (-0.02%)
AAPL   146.30 (-0.07%)
MSFT   249.49 (+0.12%)
META   140.81 (+1.32%)
GOOGL   102.37 (+0.93%)
AMZN   120.68 (-0.22%)
TSLA   238.72 (-0.87%)
NVDA   133.40 (+0.99%)
NIO   15.09 (-5.92%)
BABA   84.73 (+0.40%)
AMD   69.03 (+1.60%)
T   15.50 (-2.70%)
MU   54.32 (-0.75%)
CGC   2.98 (-2.93%)
F   12.39 (-0.96%)
GE   66.64 (-1.19%)
DIS   101.14 (+0.34%)
AMC   7.35 (+0.27%)
PYPL   95.08 (+1.33%)
PFE   43.35 (-1.75%)
NFLX   238.26 (+0.65%)
NASDAQ:PLXP

PLx Pharma - PLXP Stock Forecast, Price & News

$0.60
+0.03 (+6.12%)
(As of 10/6/2022 11:38 AM ET)
Add
Compare
Today's Range
$0.60
$0.60
50-Day Range
$0.48
$2.59
52-Week Range
$0.46
$19.83
Volume
486 shs
Average Volume
288,486 shs
Market Capitalization
$17.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

PLx Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
2,818.3% Upside
$16.50 Price Target
Short Interest
Healthy
2.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.04) to ($1.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

461st out of 1,072 stocks

Pharmaceutical Preparations Industry

207th out of 534 stocks

PLXP stock logo

About PLx Pharma (NASDAQ:PLXP) Stock

PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.

Receive PLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

PLXP Stock News Headlines

"The Most Critical Metal for Global Economies"
The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year.
PLXP Aug 2022 5.000 call
PLx Pharma downgraded at Oppenheimer after Q2 miss
PLx Pharma Q2 Loss Top Estimates, But Revenues Miss; Stock Down 15%
"The Most Critical Metal for Global Economies"
The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year.
A Preview Of PLx Pharma's Earnings
PLXP PLx Pharma Inc.
PLx Pharma: Q4 Earnings Insights
PLx Pharma's Earnings Outlook
See More Headlines
Receive PLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

PLXP Company Calendar

Last Earnings
8/12/2022
Today
10/06/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PLXP
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+2,650.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-46,130,000.00
Net Margins
-377.98%
Pretax Margin
-377.98%

Debt

Sales & Book Value

Annual Sales
$8.21 million
Book Value
$1.30 per share

Miscellaneous

Free Float
26,530,000
Market Cap
$17.48 million
Optionable
Not Optionable
Beta
3.89

Key Executives

  • Mr. Michael J. ValentinoMr. Michael J. Valentino (Age 68)
    Exec. Chairman
    Comp: $393.75k
  • Ms. Natasha Giordano (Age 62)
    CEO, Pres & Director
    Comp: $884.88k
  • Ms. Rita M. O'Connor CPA (Age 54)
    CPA, CFO and Head of Manufacturing & Supply Chain
    Comp: $623.23k
  • Mr. Ronald R. Zimmerman (Age 69)
    Founder & Sr. Advisor
  • Mr. Tom Long
    VP of Manufacturing & Technical Operations
  • Ms. Janet M. Barth
    VP of Investor Relations & Corp. Communications
  • Ms. Joanne Cotignola
    VP of Marketing
  • Mr. Patrick M. Lonergan (Age 87)
    Member of Chief Exec. Officer Advisory Group
  • Mr. Charles Edmund Sheedy C.F.A. (Age 75)
    CFA, Member of Chief Exec. Officer Advisory Group
  • Mr. Harris Kaplan M.B.A. (Age 70)
    MBA, Member of Chief Exec. Officer Advisory Group













PLXP Stock - Frequently Asked Questions

Should I buy or sell PLx Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PLXP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLXP, but not buy additional shares or sell existing shares.
View PLXP analyst ratings
or view top-rated stocks.

What is PLx Pharma's stock price forecast for 2022?

3 Wall Street analysts have issued 12 month price targets for PLx Pharma's shares. Their PLXP share price forecasts range from $12.00 to $21.00. On average, they expect the company's stock price to reach $16.50 in the next year. This suggests a possible upside of 2,818.3% from the stock's current price.
View analysts price targets for PLXP
or view top-rated stocks among Wall Street analysts.

How have PLXP shares performed in 2022?

PLx Pharma's stock was trading at $8.01 at the beginning of 2022. Since then, PLXP stock has decreased by 92.9% and is now trading at $0.5654.
View the best growth stocks for 2022 here
.

When is PLx Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our PLXP earnings forecast
.

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc. (NASDAQ:PLXP) released its earnings results on Friday, August, 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.04. The biotechnology company earned $0.48 million during the quarter, compared to analysts' expectations of $3.65 million. PLx Pharma had a negative trailing twelve-month return on equity of 205.59% and a negative net margin of 377.98%.

What other stocks do shareholders of PLx Pharma own?
When did PLx Pharma IPO?

(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

How do I buy shares of PLx Pharma?

Shares of PLXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $0.57.

How much money does PLx Pharma make?

PLx Pharma (NASDAQ:PLXP) has a market capitalization of $16.48 million and generates $8.21 million in revenue each year. The biotechnology company earns $-46,130,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The official website for the company is www.plxpharma.com. The biotechnology company can be reached via phone at (973) 409-6541, via email at lwilson@insitecony.com, or via fax at 713-842-3052.

This page (NASDAQ:PLXP) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.